Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common pill replace CPAP for opioid users?

NCT ID NCT06043830

Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug acetazolamide can improve sleep-disordered breathing in 39 adults with chronic pain who use opioids. Participants took either the drug or a placebo for one week each. The goal was to see if the pill could reduce sleep apnea events as an alternative to CPAP machines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acetazolamide
What this could lead to
If it works, this could offer a pill-based alternative to CPAP machines for treating sleep apnea in people who take opioids for chronic pain.
What could go wrong
This is a small, short-term study (39 people, 1 week each on drug and placebo). Results may not hold up in larger or longer trials, and acetazolamide can cause side effects like tingling or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

39 people

The number who actually took part.

Started

Oct 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18+ * Chronic pain * Chronic opioid use (daily use for \>3 months duration) with \>/= 20 oral Morphine Equivalent Dose (MEqD) per day * Apnea-hypopnea index \>/= 10 events/hr (hypopnea definition: ≥ 3% desaturation or arousal criteria per American Academy of Sleep Medicine 2012 scoring rules) Exclusion Criteria: * Use of opioids outside medical supervision (e.g. recreational use) * Unable or unwilling to withhold any ongoing SDB treatment (e.g. CPAP) for the duration of the study * Urgent need to initiate effective SDB therapy * Chronic lung disease (other than well-controlled asthma) * Active cardiac disease including heart failure, chest pain, or heart rhythm problems * Neurological or developmental problems affecting breathing * Major sleep disorders other than sleep apnea * Chronic kidney disease * Cirrhosis of the liver * Active cancer treatment or limited life expectancy * Psychiatric disease other than controlled mood disorders * Use of diuretics, potassium supplementation, or medications that may affect potassium * Allergy to study drug or related compounds including sulfa drugs * Know electrolyte disturbances * Hospitalized in the last 90 days or anticipated hospitalization within 3 months * Alcohol use \>2 standard drinks per day * Presence of tracheostomy or artificial airway * Prisoners * Pregnancy or anticipating pregnancy in next 2 months, or nursing * Unable or unwilling to provide informed consent * Unable to follow study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central sleep apnea syndrome Chronic Pain chronic pain syndrome obstructive sleep apnea syndrome opioid abuse sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central sleep apnea Chronic pain Obstructive sleep apnea Opioid use Sleep-disordered breathing

Contacts and locations

Locations

  • University of California San Diego

    San Diego, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.